申联生物晚间公告，公司拟使用2.37亿元的自有资金及自筹资金（包括银行并购贷款），通过全资子公 司上海本天成生物医药有限公司以股权转让及增资的方式取得联营公司扬州世之源生物科技有限责任公 司的控股权。交易完成后，上海本天成持有世之源的股权由16.99%增加到40.65%，上海申源启航投资 7995.64万元取得世之源新增的10.35%股权，上海本天成及上海申源启航将合计持有世之源51.00%的股 权，公司能够控制世之源51%股权的表决权，世之源成为公司的控股孙公司，纳入上市公司合并报表范 围。 ...

Core Viewpoint - UBI has reduced its stake in Shenglian Bio (600201) by 12,319,240 shares, representing 3% of the total share capital, decreasing its ownership from 10.52% to 7.52% [1] Group 1: Shareholding Changes - UBI's share reduction was executed at a price range of 8.80-9.89 CNY per share, totaling approximately 111 million CNY [1] - The reduction plan commenced on November 13, 2025, and was completed on February 9, 2026, without changing the controlling shareholder or actual controller of the company [1] Group 2: Financial Performance - Shenglian Bio anticipates a net loss of approximately 20 million CNY for 2025, which is a 55% improvement compared to the 2024 loss [1] - The adjusted net loss is expected to be around 23.5 million CNY, reflecting a 51% reduction [1] - The improvement in losses is attributed to cost reduction and efficiency enhancement, despite increased competition in the animal health industry leading to lower product prices and higher accounts receivable impairment losses [1][3] Group 3: Stock Performance - Over the past week (February 5 to 11, 2026), Shenglian Bio's stock price fluctuated by 3.63%, with a high of 9.87 CNY on February 10 and a low of 9.24 CNY on February 6 [2] - Following the completion of the share reduction announcement on February 9, the stock price rose by 3.32% with a trading volume increase (turnover rate of 1.06%) [2] - On February 11, the closing price was 9.71 CNY, reflecting a single-day increase of 1.04% [2]

Core Viewpoint - United Biomedical, Inc. (UBI) has completed its share reduction plan, decreasing its stake in Shenglian Biomedical (Shanghai) Co., Ltd. from 10.52% to 7.52% through the sale of 12,319,240 shares, which constitutes 3.00% of the company's total share capital [1][2][3]. Shareholder Holding Situation - Before the reduction plan, UBI held 43,199,898 shares, representing 10.52% of the total share capital of Shenglian Biomedical [1]. - The shares were acquired prior to the company's initial public offering and have been tradable since October 28, 2020 [1]. Implementation Results of the Reduction Plan - UBI's reduction plan was disclosed on October 23, 2025, with a maximum intended reduction of 12,319,320 shares [2]. - As of February 9, 2026, UBI successfully reduced its holdings by 12,319,240 shares, achieving the planned reduction [2]. Changes in Equity - Following the reduction, UBI's total shareholding decreased from 33,960,458 shares to 30,880,658 shares, with the ownership percentage dropping from 8.27% to 7.52% [3][4]. - This change in equity does not trigger a mandatory tender offer and will not affect the company's controlling shareholder or actual controller [3][4]. Other Notes - The reduction was executed in compliance with previously disclosed plans and does not involve any changes to the company's governance structure or ongoing operations [4][5]. - UBI has no concerted actions with other parties regarding this shareholding change [3].

证券代码：688098 证券简称：申联生物 公告编号：2026-004 申联生物医药(上海)股份有限公司 关于持股 5%以上股东权益变动触及 1%刻度及 减持计划完成暨减持股份结果公告 信息披露义务人UNITED BIOMEDICAL,INC.保证向本公司提供的信息真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏，并对其真实性、准确性和 完整性依法承担法律责任。本公司董事会及全体董事保证公告内容与信息披露义 务人提供的信息一致。 重要内容提示： 本次减持计划实施前，美国联合生物医药公司（UNITED BIOMEDICAL,I NC.以下简称"UBI"）持有申联生物医药（上海）股份有限公司（以下简称"公 司"或"申联生物"）43,199,898 股股份，占公司总股本的 10.52%。上述股份来源 为公司首次公开发行股票并上市前取得，且已于 2020 年 10 月 28 日后上市流通。 减持计划的实施结果情况 2025 年 10 月 23 日，公司在上海证券交易所网站（www.sse.com.cn）披 露《申联生物医药(上海)股份有限公司持股 5%以上股东减持股份计划公告》 （公告编号：2025-037）。 ...

Core Viewpoint - The company Shenyuan Biological (688098.SH) has completed a share reduction plan, with UBI reducing its stake by 3.00% of the total share capital [1] Group 1 - UBI has reduced its holdings by 12.3192 million shares through centralized bidding and block trading [1] - The share reduction plan was officially completed as of February 9, 2026 [1]

Core Viewpoint - The animal health sector experienced a rise of 1.15% on February 3, with *ST Green康 leading the gains, while the overall market indices also showed positive performance [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4067.74, up by 1.29% [1]. - The Shenzhen Component Index closed at 14127.1, up by 2.19% [1]. Group 2: Individual Stock Performance - *ST Green康 (002868) closed at 36.70, with a gain of 3.29% and a trading volume of 11,000 lots, amounting to 39.61 million yuan [1]. - 回盛生物 (300871) closed at 28.30, up by 2.83%, with a trading volume of 166,400 lots and a turnover of 467 million yuan [1]. - 大禹生物 (920970) closed at 8.14, increasing by 2.13%, with a trading volume of 23,300 lots and a turnover of 18.92 million yuan [1]. - 普莱柯 (603566) closed at 14.00, up by 2.04%, with a trading volume of 66,100 lots and a turnover of 91.87 million yuan [1]. - 驱动力 (920275) closed at 9.15, increasing by 1.78%, with a trading volume of 14,900 lots and a turnover of 13.61 million yuan [1]. - 永顺生物 (920729) closed at 9.43, up by 1.73%, with a trading volume of 52,100 lots and a turnover of 48.48 million yuan [1]. - 科前生物 (688526) closed at 16.18, increasing by 1.25%, with a trading volume of 29,000 lots and a turnover of 46.60 million yuan [1]. - 申联生物 (688098) closed at 9.45, up by 0.96%, with a trading volume of 29,700 lots and a turnover of 27.90 million yuan [1]. - 生物股份 (600201) closed at 16.42, increasing by 0.86%, with a trading volume of 400,700 lots and a turnover of 655 million yuan [1]. - 瑞普生物 (300119) closed at 19.16, up by 0.63%, with a trading volume of 60,400 lots and a turnover of 115 million yuan [1]. Group 3: Capital Flow - The animal health sector saw a net outflow of 155 million yuan from institutional investors, while retail investors contributed a net inflow of 119 million yuan [2]. - The main capital flow data indicates that 中牧股份 (600195) had a net inflow of 5.91 million yuan from institutional investors [3]. - 普莱柯 (603566) experienced a net inflow of 5.90 million yuan from institutional investors, while retail investors had a net outflow of 12.09 million yuan [3]. - *ST Green康 (002868) had a net inflow of 2.82 million yuan from institutional investors, with retail investors contributing a net inflow of 2.25 million yuan [3].

Core Viewpoint - The company Shenyuan Biological (688098.SH) has received a notification from UNITED BIOMEDICAL, INC. (UBI) regarding a change in equity holdings, indicating a reduction in UBI's shareholding in the company [1] Summary by Relevant Sections - UBI has reduced its shareholding by 7.10404 million shares, which accounts for 1.73% of the company's total share capital [1] - The reduction occurred between December 4, 2025, and January 30, 2026, with 1.97104 million shares sold through centralized bidding and 5.133 million shares sold via block trading [1] - Following this equity change, UBI's ownership in the company decreased from 10.00% to 8.27% [1]

Core Viewpoint - United Biomedical, Inc. (UBI) has reduced its stake in Shenglian Biological (688098.SH) by 7.104 million shares, representing 1.73% of the company's total share capital, which has decreased UBI's ownership from 10.00% to 8.27% [1] Group 1 - UBI's share reduction occurred between December 4, 2025, and January 30, 2026 [1] - The reduction included 1.97104 million shares sold through centralized bidding and 5.133 million shares sold via block trading [1] - The equity change triggered a notification as it touched the 1% threshold [1]

一、 信息披露义务人及其一致行动人的基本信息 证券代码：688098 证券简称：申联生物 公告编号：2026-003 申联生物医药（上海）股份有限公司 关于持股 5%以上股东权益变动触及 1%刻度的 提示性公告 信息披露义务人 UNITED BIOMEDICAL, INC.保证向本公司提供的信 息真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏，并对其真 实性、准确性和完整性依法承担法律责任。本公司董事会及全体董事保证 公告内容与信息披露义务人提供的信息一致。 公司于近日收到 UNITED BIOMEDICAL,INC（. 以下简称"UBI"）出具的《UBI 关于权益变动触及 1%刻度的告知函》，UBI 于 2025 年 12 月 4 日至 2026 年 1 月 30 日期间减持公司股份 710.404 万股，占公司总股本的 1.73%，其中通过集中 竞价方式减持公司股份 197.104 万股，通过大宗交易方式减持公司股份 513.3 万 股。本次权益变动后，UBI 持有公司股份比例由 10.00%降至 8.27%，权益变动 触及 1%刻度。具体情况如下： | 投资者名称 | 变动前股数 | 变动前比例 ...

Group 1 - On January 30, 2023, Shenlian Bio conducted a block trade of 3.08 million shares, with a transaction amount of 27.104 million yuan, accounting for 35.9% of the total transaction volume for that day [1] - The transaction price was 8.8 yuan, which represents a discount of 7.66% compared to the market closing price of 9.53 yuan [1]